Compare iShares MSCI Japan ETF (EWJ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Mesoblast Limited — how do they compare? iShares MSCI Japan ETF trades at $97.69 (market cap $23.87B), while Mesoblast Limited trades at $14.32 (market cap $1.75B). The key difference: iShares MSCI Japan ETF is far larger — about 13.6× Mesoblast Limited's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Mesoblast Limited for 14 Days on average.
| EWJ | MESO | |
|---|---|---|
Market Cap | $23.87B | $1.75B |
Volume | 5,412,820 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $20.96 |
52-Week Low | $78.36 | $13.19 |
Typical Hold Time | 56 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.44, down 0.9% on the day amid mixed technical signals. The ETF shows neutral momentum with RSI readings around 50 and faces immediate resistance at $98. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes while facing fiscal challenges and yen volatility.
The outlook remains balanced with international ETF performance showing strength but Japanese equities facing headwinds from rising yields and currency pressures. Key risks include BOJ policy missteps and global bond market volatility, while potential catalysts include sustained international diversification trends and yen stabilization efforts.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
